Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

ant clinical advancements during the coming year. In the bavituximab anti-viral program, we recently received a significant external validation of this program when the DTRA awarded Peregrine a multi-year contract worth up to $44.4 million to develop bavituximab for the treatment and prevention of viral hemorrhagic fevers. We expect this contract will help advance all of our bavituximab anti-viral programs."

Mr. King added, "Similarly, we strengthened the foundation for progress in the Cotara clinical program by initiating additional sites in two ongoing trials of Cotara in patients with GBM. Data was presented at the 2008 ASCO Annual Meeting reinforcing Cotara's safety and its ability to target radiation precisely to the brain tumor while avoiding healthy tissue, further reinforcing its potential as a possible new treatment for GBM. We look forward to generating more data on Cotara's impact on tumor status and patient survival over the course of this fiscal year."

Mr. King concluded, "We believe that the company's future has never looked brighter. With multiple Phase II trials underway or soon to begin, we expect a consistent flow of clinical data throughout the upcoming year. The expected new clinical trial data we are in the process of generating along with anticipated increased contract manufacturing revenues and continued progress in our preclinical anti-viral programs are setting the stage for what we believe will be a positive and productive FY 2009."

At April 30, 2008, Peregrine had $15.1 in cash and cash equivalents compared to $16.0 million at April 30, 2007. The company's FY 2008 Annual Report on Form 10-K to be filed today will include an audit opinion with a "going concern" qualification. The qualification is a statement in the audit opinion of Ernst & Young LLP, the company's independent registered public accounting firm, expressing substantial doubt, based upon Peregrine's current financial resources, as to whether it can continue
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Keck Graduate Institute,(KGI) today announced a partnership with ... forum to help women managers advance in the,life ... forum from Jan. 13-18, 2008. Attendees will,have the ... executives from,pharmaceutical, medical device and biotechnology companies along ...
... 21 Nile Therapeutics Inc., (OTC,Bulletin Board: SPDU) ... disease, is pleased to announce the,appointments of Daron ... as the Vice President of Development. Mr. ... Chief Operating Officer,and was appointed Chief Financial Officer ...
... of Physics Dr. Satyendra Kumar recently was honored ... Directors Award for Excellence for recognition of exceptional ... matter physics proposals. In all, seven program directors ... Arlington, Va. , The NSF Directors Award ...
Cached Biology Technology:KGI and Smith College Establish Leadership Forum for Women in Bioscience 2Nile Therapeutics, Inc. Adds to Executive Management Team 2Nile Therapeutics, Inc. Adds to Executive Management Team 3Nile Therapeutics, Inc. Adds to Executive Management Team 4
(Date:4/18/2014)... X-ray crystallography and nuclear magnetic resonance imaging (NMR) to ... but such efforts have long been hampered by the ... molecule and often in ordered and crystalized form to ... peer into the structure of most molecules. , Harvard ... thing of the past. , A team of ...
(Date:4/18/2014)... twist to the story of how barnyard chickens came to ... the journal Proceedings of the National Academy of Sciences ... lived 200-2300 years ago in Europe, researchers report that just ... far different from the chickens we know today. , The ... modern domestic chickens -- such as their yellowish skin -- ...
(Date:4/18/2014)... Calif. A team of researchers led by ... been selected to receive a $7.5 million Department of ... simple and basic scientific foundations for the predictable design ... a wide diversity of structures from plants and animals, ... are taking what biological systems have constructed over millions ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Ancient DNA offers clues to how barnyard chickens came to be 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... have a promising new approach to combating deadly human viruses ... microbiology professor Shou-Wei Ding , and his 20 years ... prove his theory true. Researchers led by Ding, who ... Genome Biology , have discovered that, like plants and invertebrate ...
... of Toronto research has found that purple loosestrife an ... nutrients and can degrade habitats for wildlife has evolved ... spread to northern Ontario. This has allowed populations of ... more than 30-fold increase in seed production. "The ...
... tree species Dracaena kaweesakii from Thailand is characterized ... 12 m in both height and crown diameter, and has ... with bright orange filaments, all highly distinctive features. The study ... access journal Phytokeys by an international ...
Cached Biology News:Researchers discover innate virus-killing power in mammals 2Researchers discover innate virus-killing power in mammals 3Researchers discover innate virus-killing power in mammals 4Natural selection enables purple loosestrife to invade northern Ontario 2
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
... Clear amber to slightly cloudy liquid. ... vials per set, each containing 10 ... in the following proportions by weight: ... (mannide monooleate emulsifier), and 0.1% ...
Biology Products: